We have previously shown from our laboratory that the DPP-4 inhibitor sitagliptin reduces the mineralization of VICs in vitro, decreases calcific lesion formation in eNOS−/− mice, and improves aortic valve performance accompanied by a reduction in the calcium deposits in a rabbit CAVD model [19]. Here, DPP4 is linked to congenital bilateral aplasia of vas deferens from CFTR mutation.